Daewoong Biopharmaceutical Meropenem 1g (Meropenem Trihydrate)

Adult administration

As Meropenem hydrate, administer 0.5 to 1 g (potency) daily, divided into 2 to 3 doses via slow intravenous infusion for more than 30 minutes. In cases of suspected infections in patients with pathogenic pneumonia, peritonitis, and neutropenia, administer 1 g (potency) every 8 hours via slow intravenous infusion. In cystic fibrosis and meningitis, administer 2 g (potency) every 8 hours via slow intravenous infusion.

Child administration

For bacterial meningitis in children over 3 months, administer 40 mg per kg of body weight every 8 hours via slow intravenous infusion for more than 30 minutes, based on the pathogen's susceptibility and the patient's condition.

This medication should not be used in patients who have experienced severe allergic reactions or shock from this drug or similar drugs in the past. Patients taking sodium valproate should be cautious as this drug may lower the blood concentration of valproate, increasing the risk of seizures. Patients with a history of allergies or those who have easily manifest allergic symptoms such as asthma and rashes in their family should also use it cautiously. Renal impairment patients may experience prolonged drug presence in the body, which can lead to central nervous system symptoms or seizures, thus requiring dose adjustment. Patients with epilepsy or central nervous system diseases may also experience seizures or consciousness disorders when using this drug, so caution is advised. Special care is needed for elderly patients, patients in poor general condition, and infants under 3 months. This drug may cause allergic reactions such as rashes, hives, fever, and dyspnea during use, so if these symptoms occur, therapy should be stopped immediately and medical personnel notified. Regular monitoring is necessary due to potential blood abnormalities, liver dysfunction, renal impairment, severe diarrhea, and central nervous system abnormal symptoms. If symptoms of rhabdomyolysis such as muscle pain, weakness, or dark urine occur during administration, usage should be stopped immediately. This drug may interact with other medications, so patients should inform their healthcare provider about any drugs they are taking, particularly when used with anticonvulsants, hormonal agents, and anticoagulants. Women who are pregnant or may become pregnant should carefully consider the benefits and risks of using this drug as its safety during pregnancy is uncertain. Nursing mothers should avoid breastfeeding as this drug may be secreted into breast milk. The drug should only be administered intravenously and must be used quickly after reconstitution. It should also be used within the specified time when stored. Caution is advised when driving or operating machinery as symptoms such as headache, dizziness, and mental confusion may occur. Avoid using this drug long-term or carelessly and administer only for the minimum duration necessary for treatment.

Serious side effects

Shock, anaphylactic-like reactions, hives, severe swelling (angioedema), rash, toxic epidermal necrolysis (Lyell's syndrome), Stevens-Johnson syndrome, DRESS syndrome, erythema multiforme, acute generalized exanthematous pustulosis, severe allergic reactions, severe rash with high fever, blisters, skin peeling, pain in oral/eye mucous membranes, severe skin adverse reactions, difficulty breathing or shortness of breath, asthma attacks,

Mild side effects

• Oral dysregulation
• wheezing
• dizziness
• diarrhea
• tinnitus
• sweating
• rash
• flush
• erythema
• itching

This drug should be stored in a sealed container to avoid contact with air and kept at a temperature between 1 and 30 degrees Celsius, which is safe for storage. Proper storage will maintain the drug's effectiveness and ensure safe use.

Appearance

Vials filled with crystalline powder ranging from white to pale yellow

Package unit

10 vials per box